Sovaldi Deal Tames Hardliners But India’s Sec 3(d) Lingers On
This article was originally published in PharmAsia News
Executive Summary
Gilead played a master stroke aligning with leading Indian generic companies for ensuring low cost sofosbuvir in India and 90-plus countries. But its patent fight with other drug makers and patient groups is far from over.